Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 50
Filtrar
1.
J Inorg Biochem ; 164: 59-69, 2016 11.
Artigo em Inglês | MEDLINE | ID: mdl-27586814

RESUMO

Semax is a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) that encompasses the sequence 4-7 of N-terminal domain of the adrenocorticotropic hormone and a C-terminal Pro-Gly-Pro tripeptide. N-terminal amino group acetylation (Ac-Semax) modulates the chemical and biological properties of parental peptide, modifying the ability of Semax to form complex species with Cu(II) ion. At physiological pH, the main complex species formed by Ac-Semax, [CuLH-2]2-, consists in a distorted CuN3O chromophore with a weak apical interaction of the methionine sulphur. Such a complex differs from the Cu(II)-Semax complex system, which exhibits a CuN4 chromophore. The reduced ligand field affects the [CuLH-2]2- formal redox potential, which is more positive than that of Cu(II)-Semax corresponding species. In the amino-free form, the resulting complex species is redox-stable and unreactive against ascorbic acid, unlike the acetylated form. Semax acetylation did not protect from Cu(II) induced toxicity on a SH-SY5Y neuroblastoma cell line, thus demonstrating the crucial role played by the free NH2 terminus in the cell protection. Since several brain diseases are associated either to Cu(II) or Zn(II) dyshomeostasis, here we characterized also the complex species formed by Zn(II) with Semax and Ac-Semax. Both peptides were able to form Zn(II) complex species with comparable strength. Confocal microscopy imaging confirmed that peptide group acetylation does not affect the Zn(II) influx in neuroblastoma cells. Moreover, a punctuate distribution of Zn(II) within the cells suggests a preferred subcellular localization that might explain the zinc toxic effect. A future perspective can be the use of Ac-Semax as ionophore in antibody drug conjugates to produce a dysmetallostasis in tumor cells.


Assuntos
Hormônio Adrenocorticotrópico/análogos & derivados , Complexos de Coordenação , Cobre , Ionóforos , Fragmentos de Peptídeos , Zinco , Acetilação , Hormônio Adrenocorticotrópico/síntese química , Hormônio Adrenocorticotrópico/química , Hormônio Adrenocorticotrópico/farmacologia , Linhagem Celular Tumoral , Complexos de Coordenação/síntese química , Complexos de Coordenação/química , Complexos de Coordenação/farmacologia , Cobre/química , Cobre/farmacologia , Humanos , Ionóforos/síntese química , Ionóforos/química , Ionóforos/farmacologia , Fragmentos de Peptídeos/síntese química , Fragmentos de Peptídeos/química , Fragmentos de Peptídeos/farmacologia , Zinco/química , Zinco/farmacologia
2.
Eksp Klin Farmakol ; 77(6): 30-2, 2014.
Artigo em Russo | MEDLINE | ID: mdl-25102733

RESUMO

The influence two original derivatives of a therapeutically important peptide, bearing arachidonic acid residue with semax and proglyprol, upon platelet aggregation have been studied in vitro. It is established that both derivatives, in contrast to the parent peptide, possess moderate anti-aggregant properties and produce a dose-dependent decrease in the interplatelet interaction induced by ADP, epinephrine, and arachidonic acid within the concentration range of 0.018 - 1.8 mM. This activity was more pronounced for arachidonoylsemax in comparison with arachidonoylproglyprol.


Assuntos
Hormônio Adrenocorticotrópico/análogos & derivados , Ácido Araquidônico/química , Fármacos Neuroprotetores/síntese química , Oligopeptídeos/síntese química , Fragmentos de Peptídeos/síntese química , Inibidores da Agregação Plaquetária/síntese química , Agregação Plaquetária/efeitos dos fármacos , Prolina/análogos & derivados , Difosfato de Adenosina/farmacologia , Hormônio Adrenocorticotrópico/síntese química , Hormônio Adrenocorticotrópico/farmacologia , Ácido Araquidônico/farmacologia , Plaquetas/citologia , Plaquetas/efeitos dos fármacos , Células Cultivadas , Desenho de Fármacos , Epinefrina/farmacologia , Humanos , Fármacos Neuroprotetores/farmacologia , Oligopeptídeos/farmacologia , Fragmentos de Peptídeos/farmacologia , Inibidores da Agregação Plaquetária/farmacologia , Prolina/síntese química , Prolina/farmacologia , Relação Estrutura-Atividade
4.
J Pept Sci ; 13(8): 513-8, 2007 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-17617799

RESUMO

Synthetic peptide, corresponding to the amino acid sequence 11-24 of human adrenocorticotropic hormone (ACTH), was labeled with tritium (specific activity of 22 Ci/mmol). [(3)H]ACTH (11-24) was found to bind to rat adrenal cortex membranes with high affinity and specificity (K(d) = 1.8 +/- 0.1 nM). Twenty nine fragments of ACTH (11-24) have been synthesized and their ability to inhibit the specific binding of [(3)H]ACTH (11-24) to adrenocortical membranes has been investigated. Unlabeled fragment ACTH 15-18 (KKRR) was found to replace in a concentration-dependent manner [(3)H]ACTH (11-24) in the receptor-ligand complex (K(i) = 2.3 +/- 0.2 nM). ACTH (15-18) was labeled with tritium (specific activity of 20 Ci/mmol). [(3)H]ACTH (15-18) was found to bind to rat adrenal cortex membranes with high affinity (K(d) = 2.1 +/- 0.1 nM). The specific binding of [(3)H]ACTH (15-18) was inhibited by unlabeled ACTH (11-24) (K(i) = 2.2 +/- 0.1 nM). ACTH (15-18) at the concentration range of 1-1000 nM did not affect the adenylate cyclase activity in adrenocortical membranes.


Assuntos
Córtex Suprarrenal/metabolismo , Hormônio Adrenocorticotrópico/metabolismo , Membrana Celular/metabolismo , Peptídeos/metabolismo , Receptores da Corticotropina/metabolismo , Adenilil Ciclases/metabolismo , Hormônio Adrenocorticotrópico/síntese química , Hormônio Adrenocorticotrópico/farmacologia , Animais , Relação Dose-Resposta a Droga , Ativação Enzimática/efeitos dos fármacos , Humanos , Peptídeos/síntese química , Peptídeos/farmacologia , Ligação Proteica/fisiologia , Ratos , Trítio/química
5.
Neuro cienc ; 3(1): 5-7, ene.-abr. 1996. tab
Artigo em Espanhol | LILACS | ID: lil-216690

RESUMO

Los niños con encelopatias cronicas pueden presentar retraso del desarrollo psicomotor y en algun momento de su evolucion, crisis de espasmos con tazado electroencefalografico hipsarritmico, constituyendo un sindrome de west sintomatico. Presentamos un analisis y seguimiento evolutivo de 9 niños que, si presentaron hipsarritmia, no sufrieron espasmos. Prevaleciendo en mujeres (8:1), la hipsarritmia comenzo en la mayoria de los pacientes (77.8 por ciento) antes de los meses. El factor etiologico fue, en todos los pacientes, un daño encefalico previo. Clinicamente los niños presentaron examen neurologico anormal, solo 6 niños presentaron convulciones y ninguno presento crisis de espasmos. Los electroencefalogramas mostraron algun tipo de hipsarritmia. Se evalua el resultado del tratamiento con ACTH instaurado. Resaltamos la existencia de hipsarritmia sin crisis de espasmos y destacamos que 3 niños de nuestra serie presentaron, como caracteristica propia distintiva, la ausencia de manifestaciones convulsivas


Assuntos
Humanos , Criança , Espasmos Infantis/complicações , Espasmos Infantis/diagnóstico , Espasmos Infantis/etiologia , Espasmos Infantis/enfermagem , Espasmos Infantis/patologia , Hormônio Adrenocorticotrópico , Hormônio Adrenocorticotrópico/efeitos adversos , Hormônio Adrenocorticotrópico/análise , Hormônio Adrenocorticotrópico/síntese química , Hormônio Adrenocorticotrópico/farmacologia , Hormônio Adrenocorticotrópico/uso terapêutico , Hormônio Adrenocorticotrópico/toxicidade
6.
J Recept Res ; 13(1-4): 229-44, 1993.
Artigo em Inglês | MEDLINE | ID: mdl-8383754

RESUMO

A biotinylated derivative of [beta-Ala1,Lys17]-ACTH1-17-NH-(CH2)4-NH2 (ACTH1-17) was synthesized and biologically characterized. The heptadecapeptide with free N-terminus and blocked side-chains was prepared by the solid-phase method using TentaGel resin and a 4-aminobutylamide linker. Biotinyl-beta-Ala-OH was then coupled to the terminal amino group and the resulting [N alpha-(biotinyl-beta-alanyl)-beta-Ala1,Lys17]-ACTH1-17-NH-(CH2)4-N H2 (Bio-ACTH1-17) cleaved from the resin, purified and analyzed. Competition binding assays with mouse B16-F1 and human D10 and HBL melanoma cells using [125I]-alpha-MSH as radioligand gave dissociation constants for Bio-ACTH1-17 of 1.67 +/- 0.07 nM (B16-F1), 0.02 +/- 0.005 nM (D10) and 0.21 +/- 0.02 nM (HBL). The EC50 for Bio-ACTH1-17 in the B16 melanin assay was 4.15 +/- 1.0 nM. Analysis of the binding characteristics of [125I]-Bio-ACTH1-17 demonstrated that in human melanoma cells this radioligand was displaced by ACTH1-17 as well as alpha-MSH whereas in B16-F1 cells the tracer was only displaced from the binding site by ACTH1-17. Studies of Bio-ACTH1-17 with streptavidin showed that the peptide is to a large extent trapped specifically through reaction with biotin. These results demonstrate that (1) the biological characteristics of Bio-ACTH1-17 are almost identical to those of ACTH1-17, (2) Bio-ACTH1-17 is bound by avidin, and (3) Bio-ACTH1-17 may become a useful tool for MSH receptor targeting.


Assuntos
Hormônio Adrenocorticotrópico/síntese química , Biotina/análogos & derivados , Fragmentos de Peptídeos/síntese química , Receptores do Hormônio Hipofisário/metabolismo , Hormônio Adrenocorticotrópico/metabolismo , Hormônio Adrenocorticotrópico/farmacologia , Sequência de Aminoácidos , Animais , Bioensaio , Biotina/síntese química , Biotina/metabolismo , Biotina/farmacologia , Humanos , Melaninas/biossíntese , Melanoma Experimental/metabolismo , Camundongos , Dados de Sequência Molecular , Fragmentos de Peptídeos/metabolismo , Fragmentos de Peptídeos/farmacologia , Sensibilidade e Especificidade , Células Tumorais Cultivadas
7.
Biochemistry ; 24(8): 1960-5, 1985 Apr 09.
Artigo em Inglês | MEDLINE | ID: mdl-2990545

RESUMO

Biotinylated photoaffinity derivatives of adrenocorticotropin (ACTH) are potentially useful tools for the identification of ACTH receptors. The hormone can be attached covalently to its receptor by photoactivation, and the presence of biotin in the molecule facilitates isolation of the solubilized hormone-receptor complex on columns of immobilized succinoylavidin (Suc-avidin). Six photoprobes of ACTH1-24 have been prepared by reacting ACTH1-24, [25-biocytin]ACTH1-25 amide, and [25-dethiobiocytin]ACTH1-25 amide with either 4- or 5-azido-2-nitrophenylsulfenyl (4-NAPS and 5-NAPS, respectively) chlorides in acetic acid. The homogeneity of the photoprobes was carefully monitored by thin-layer chromatography and amino acid analyses of acid hydrolysates. The presence of underivatized starting material in the photoprobes was critically scrutinized by high-pressure liquid chromatography and was estimated to be less than 0.5%. Both the 4- and 5-NAPS derivatives stimulated maximal steroidogenesis (as compared with ACTH1-24) in calf adrenal cortical cells. However, the potencies of the two isomers differed significantly. The ED50 for steroidogenesis with 5-NAPS-ACTH1-24 was 100-fold greater than the standard (ACTH1-24) while that for 4-NAPS-ACTH1-24 was only approximately 7 times greater. Although 4-NAPS-ACTH1-24 was capable of stimulating maximal adenosine cyclic 3',5'-phosphate (cAMP) production, the 5-NAPS derivative was usually not. The level of stimulation with the 5-NAPS derivative varied considerably from cell preparation to cell preparation. ACTH1-24-induced cAMP production was inhibited by 5-NAPS-ACTH1-24 or 5-NAPS-[25-dethiobiocytin]ACTH1-25 amide.(ABSTRACT TRUNCATED AT 250 WORDS)


Assuntos
Hormônio Adrenocorticotrópico/análogos & derivados , Hormônio Adrenocorticotrópico/metabolismo , Receptores de Superfície Celular/metabolismo , Glândulas Suprarrenais/metabolismo , Hormônio Adrenocorticotrópico/síntese química , Animais , Bovinos , Indicadores e Reagentes , Cinética , Masculino , Fotólise , Receptores da Corticotropina , Relação Estrutura-Atividade
10.
Int J Pept Protein Res ; 15(2): 159-66, 1980 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-6246015

RESUMO

A novel synthesis of human CLIP, a peptide corresponding to the sequence of human ACTH-(18-39) is described. The dodecapeptide chain was assembled by a combination of fragment condensation and stepwise synthesis while using N alpha-benzyloxycarbonyl and side chain tert.-butyl-derived protective groups combination. The final deprotection was performed by acidolysis in trifluoroacetic acid. The end product was purified by ion exchange chromatography on carboxymethyl cellulose.


Assuntos
Hormônio Adrenocorticotrópico/síntese química , Fragmentos de Peptídeos/síntese química , Sequência de Aminoácidos , Cromatografia em Camada Fina , Peptídeo da Parte Intermédia da Adeno-Hipófise Semelhante à Corticotropina
11.
Int J Pept Protein Res ; 13(3): 346-52, 1979 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-218890

RESUMO

Three analogs of the amino terminal nonadecopeptide of adrenocorticotropin which incorporate cystine cystine bridges between positions (5, 10), (3, 10), or (2, 10) have been synthesized. All of the peptide analogs showed reduced biological activity; however, the peptide with the 5, 10 cystine bridge was shown to possess significantly higher lipolytic activity in rat fat cells than the peptides with a 3, 10 or 2, 10 cystine bridge.


Assuntos
Hormônio Adrenocorticotrópico/síntese química , Peptídeos/síntese química , Glândulas Suprarrenais/análise , Sequência de Aminoácidos , Aminoácidos/análise , Animais , Bioensaio , Peso Molecular , Peptídeos/análise , Ratos
13.
Int J Pept Protein Res ; 8(6): 589-95, 1976.
Artigo em Inglês | MEDLINE | ID: mdl-186422

RESUMO

The peptide [15, 16-D-lysine, 17, 18-D-arginine]-adrenocorticotropin-(1-19) and an all-D-retropeptide related to the amino terminal octadecapeptide of adrenocorticotropin have been synthesized by the solid-phase method. The nonadecapeptide was shown to possess 10-15% of the steroidogenic activity and 3% of the lipolytic activity of adrenocorticotropin-(1-19). The all-D-retropeptide showed no activity and exhibited no inhibitory activity in steroidogenesis and lipolysis.


Assuntos
Hormônio Adrenocorticotrópico/síntese química , Peptídeos/síntese química , Hormônio Adrenocorticotrópico/análise , Hormônio Adrenocorticotrópico/farmacologia , Sequência de Aminoácidos , Animais , Arginina , Eletroforese em Papel , Lisina , Fatores de Terminação de Peptídeos , Peptídeos/análise , Peptídeos/farmacologia , Ratos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA